David W Garber

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. ncbi request reprint Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol
    Mohamad Navab
    Department of Medicine, University of California Los Angeles, California, USA
    Circulation 105:290-2. 2002
  2. ncbi request reprint Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins
    David W Garber
    Department of Medicine, The University of Alabama at Birmingham, Birmingham AL 35294, USA
    Curr Pharm Biotechnol 7:235-40. 2006
  3. ncbi request reprint Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice
    David W Garber
    Department of Medicine, The University of Alabama at Birmingham, BDB Room D 654, 1530 3rd Ave S, Birmingham, AL 35294 0012, USA
    Atherosclerosis 168:229-37. 2003
  4. pmc Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice
    Gaurav Nayyar
    Department of Medicine and Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Atherosclerosis 224:326-31. 2012
  5. ncbi request reprint Oral amphipathic peptides as therapeutic agents
    Srinivasa T Reddy
    Division of Cardiology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095 1679, USA
    Expert Opin Investig Drugs 15:13-21. 2006
  6. pmc Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice
    Shaila P Handattu
    Atherosclerosis Research Unit, Department of Medicine, University of Alabama, Birmingham, AL, USA
    J Lipid Res 51:3491-9. 2010
  7. pmc Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects
    Gaurav Nayyar
    Atherosclerosis Research Unit and Department of Medicine, Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Atherosclerosis 213:449-57. 2010
  8. doi request reprint Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease
    Shaila P Handattu
    Atherosclerosis Research Unit and Department of Medicine, University of Alabama at Birmingham Medical Center, Birmingham, AL 35294, USA
    Neurobiol Dis 34:525-34. 2009
  9. pmc Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice
    Shaila P Handattu
    Department of Medicine and Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Atherosclerosis 227:58-64. 2013
  10. pmc In vivo and in vitro effects of an apolipoprotein e mimetic peptide on amyloid-β pathology
    Shaila P Handattu
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA
    J Alzheimers Dis 36:335-47. 2013

Collaborators

Detail Information

Publications31

  1. ncbi request reprint Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol
    Mohamad Navab
    Department of Medicine, University of California Los Angeles, California, USA
    Circulation 105:290-2. 2002
    ..When added to the drinking water of apoE-null mice, D-4F decreased lesions by approximately 75% at the lowest dose tested (0.05 mg/mL). The marked reduction in lesions occurred independent of changes in total plasma or HDL-cholesterol...
  2. ncbi request reprint Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins
    David W Garber
    Department of Medicine, The University of Alabama at Birmingham, Birmingham AL 35294, USA
    Curr Pharm Biotechnol 7:235-40. 2006
    ..The use of peptide mimetics to study apolipoprotein function has proved to be a powerful tool, and may lead to novel therapeutic agents in the prevention of atherosclerosis and other vascular diseases...
  3. ncbi request reprint Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice
    David W Garber
    Department of Medicine, The University of Alabama at Birmingham, BDB Room D 654, 1530 3rd Ave S, Birmingham, AL 35294 0012, USA
    Atherosclerosis 168:229-37. 2003
    ....
  4. pmc Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice
    Gaurav Nayyar
    Department of Medicine and Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Atherosclerosis 224:326-31. 2012
    ....
  5. ncbi request reprint Oral amphipathic peptides as therapeutic agents
    Srinivasa T Reddy
    Division of Cardiology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095 1679, USA
    Expert Opin Investig Drugs 15:13-21. 2006
    ..In addition, the peptide D-4F stimulates the formation and cycling of pre-beta HDL. These amphipathic peptides appear to have therapeutic potential as oral agents...
  6. pmc Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice
    Shaila P Handattu
    Atherosclerosis Research Unit, Department of Medicine, University of Alabama, Birmingham, AL, USA
    J Lipid Res 51:3491-9. 2010
    ..Thus oral administration of mR18L reduces plasma cholesterol and lesion formation and inhibits monocyte adhesion...
  7. pmc Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects
    Gaurav Nayyar
    Atherosclerosis Research Unit and Department of Medicine, Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Atherosclerosis 213:449-57. 2010
    ..In this paper we have compared the properties of Ac-hE18A-NH(2) with the non-heparin binding 151-160 region of apoE linked to 18A (Ac-nhE18A-NH(2))...
  8. doi request reprint Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease
    Shaila P Handattu
    Atherosclerosis Research Unit and Department of Medicine, University of Alabama at Birmingham Medical Center, Birmingham, AL 35294, USA
    Neurobiol Dis 34:525-34. 2009
    ..These results suggest that the apo A-I mimetic peptide inhibits amyloid beta deposition and improves cognitive function via exerting anti-inflammatory properties in the brain...
  9. pmc Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice
    Shaila P Handattu
    Department of Medicine and Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Atherosclerosis 227:58-64. 2013
    ..We investigated two apoE mimetic peptides with similar long-term plasma cholesterol reducing abilities for their effects on atherosclerotic lesions in Western diet-fed female LDL-receptor (LDL-R) null mice...
  10. pmc In vivo and in vitro effects of an apolipoprotein e mimetic peptide on amyloid-β pathology
    Shaila P Handattu
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA
    J Alzheimers Dis 36:335-47. 2013
    ..ApoE is involved in various protective functions in CNS including cholesterol transport, anti-inflammatory, and antioxidant effects. An ApoE peptide would be expected to exert protective effects on neuroinflammation...
  11. ncbi request reprint Apolipoprotein E mimetic Peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits
    Himanshu Gupta
    Department of Medicine, University of Alabama at Birmingham, AL, USA
    Circulation 111:3112-8. 2005
    ....
  12. pmc Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2)
    Geeta Datta
    Department of Medicine, Atherosclerosis Research Unit, Division of Gerontology, Geriatrics and Palliative Medicine, University of Alabama at Birmingham, 1808 Seventh Avenue South, Birmingham, AL 35294, USA
    Atherosclerosis 208:134-41. 2010
    ..Such a peptide has great potential as a therapeutic agent in the management of atherosclerosis and other inflammatory diseases...
  13. doi request reprint ApoE mimetic peptide reduces plasma lipid hydroperoxide content with a concomitant increase in HDL paraoxonase activity
    Geeta Datta
    Departments of Medicine, Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Adv Exp Med Biol 660:1-4. 2010
    ..It dramatically reduces plasma cholesterol in dyslipidemic mouse and rabbit models. Recycling of apoE mimetic peptide increases the duration of preβ-HDL formation leading to extended anti-inflammatory and atheroprotective properties...
  14. ncbi request reprint Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide
    Brian J Van Lenten
    Department of Medicine, UCLA School of Medicine, University of California at Los Angeles, 90095 1679, USA
    Circulation 106:1127-32. 2002
    ..The present study tested this hypothesis...
  15. ncbi request reprint HDL therapy for cardiovascular diseases: the road to HDL mimetics
    C Roger White
    Vascular Biology and Hypertension Program, University of Alabama, Birmingham, 1046 Zeigler Research Building, 703 South 19th Street, Birmingham, AL 35294, USA
    Curr Atheroscler Rep 10:405-12. 2008
    ..The goal of this review is to discuss the current status of HDL therapeutics, with emphasis on a novel class of agent, the apolipoprotein A-I mimetic peptides, which improve the functional properties of HDL cholesterol...
  16. ncbi request reprint Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides
    G M Anantharamaiah
    Department of Medicine, Biochemistry, and Molecular Genetics and Atherosclerosis Research Unit, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Lipid Res 48:1915-23. 2007
    ..Understanding the structure and function of apoA-I and HDL through studies of the amphipathic helix motif may lead to peptide-based therapies for inhibiting atherosclerosis and other related inflammatory lipid disorders...
  17. ncbi request reprint Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity
    Geeta Datta
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Biol Chem 279:26509-17. 2004
    ....
  18. pmc Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in rats
    Oleg F Sharifov
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35216, United States
    Biochem Biophys Res Commun 436:705-10. 2013
    ..We suggest that anti-endotoxin activity of mR18L is an important anti-inflammatory property, which may increase anti-atherogenic potential of this promising orally active lipid-lowering peptide. ..
  19. ncbi request reprint ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers
    Shaila P Handattu
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Biol Chem 282:1980-8. 2007
    ..These results support the proposal that the molecular basis for the difference in the biological activities of the two peptides lies with their different interactions with membranes...
  20. ncbi request reprint Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide
    Himanshu Gupta
    Division of Cardiovascular Disease, Department of Medicine, University of Alabama, Birmingham, USA
    Circ Res 97:236-43. 2005
    ..The current studies demonstrate that L-4F reduces the expression of inflammatory markers induced by LPS and lipid A and suggest that apoAI peptide mimetics may be useful in the treatment of inflammation associated with endotoxemia...
  21. pmc Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides
    Gaurav Nayyar
    The Atherosclerosis Research Unit, Departments of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Lipid Res 53:849-58. 2012
    ..These studies support our hypothesis that the sidedness of interfacial Arg residues in the polar face of apoA-I mimetics results in differential biological properties...
  22. ncbi request reprint D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice
    Mohamad Navab
    Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90095 1679, USA
    Arterioscler Thromb Vasc Biol 25:1426-32. 2005
    ..We tested for synergy between pravastatin and D-4F by administering oral doses of each in combination that were predetermined to be ineffective when given as single agents...
  23. ncbi request reprint Apolipoprotein A-I mimetic peptides
    Mohamad Navab
    Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90095 1679, USA
    Arterioscler Thromb Vasc Biol 25:1325-31. 2005
    ..However, understanding these physical-chemical properties provides an explanation for the mechanism of action of the active peptides...
  24. ncbi request reprint Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis
    Mohamad Navab
    Department of Medicine, David Geffen School of Medicine, 10833 Le Conte Avenue, University of California, Los Angeles, Los Angeles, CA 90095 1679, USA
    Curr Opin Investig Drugs 4:1100-4. 2003
    ....
  25. doi request reprint Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A
    Oleg F Sharifov
    Department of Medicine, University of Alabama at Birmingham, AL, USA
    Innate Immun 20:867-80. 2014
    ..In conclusion, Ac-hE18A-NH2 is more effective than 4F in inhibiting LPS-mediated inflammation, which opens prospective clinical applications for Ac-hE18A-NH2. ..
  26. pmc Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease
    Ling Li
    Departments of Medicine, Pharmacology, and Genetics, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Am J Pathol 163:2155-64. 2003
    ..Our results suggest that synergistic mechanisms may be involved in the pathogenesis of atherosclerosis and AD. These findings may have important implications in the prevention and treatment of cardiovascular diseases as well as AD...
  27. ncbi request reprint Synthetic peptides: managing lipid disorders
    Gm Anantharamaiah
    Departments of Medicine, Biochemistry, and Molecular Genetics and the Atherosclerosis Research Unit, University of Alabama at Birmingham, Birmingham Alabama, USA
    Curr Opin Lipidol 17:233-7. 2006
    ..Recent publications related to the potential use of synthetic peptides for the management of lipid disorders and their vascular complications are reviewed...
  28. ncbi request reprint Apolipoprotein Mimetic Peptides as Modulators of Lipoprotein Function
    G M Anantharamaiah
    Department of Medicine, University of Alabama at Birmingham Medical Center, Birmingham, Alabama 35294, USA
    Protein Pept Lett . 2016
    ..The present review describes progress made in this field which have culminated in clinical trials in humans for both the apoA-I and apoE mimetic peptides...
  29. pmc Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review
    C Roger White
    Department of Medicine, Divisions of Cardiovascular Disease, Gerontology, Geriatric Medicine University of Alabama at Birmingham, Birmingham, AL
    J Lipid Res 55:2007-21. 2014
    ..One of these (AEM-28) has recently been given orphan drug status and is undergoing clinical trials. ..
  30. ncbi request reprint An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice
    Mohamad Navab
    David Geffen School of Medicine, UCLA, Los Angeles, California 90095 1679, USA
    Arterioscler Thromb Vasc Biol 25:1932-7. 2005
    ..To determine the properties of a peptide synthesized from D-amino acids corresponding to residues 113 to 122 in apolipoprotein (apo) J...
  31. ncbi request reprint Sustained-delivery of an apolipoprotein E-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels
    Mysore P Ramprasad
    Skye Pharma Inc, 10450 Science Center Drive, San Diego, CA 92121, USA
    J Control Release 79:207-18. 2002
    ..These results indicate that the apoE peptidomimetic encapsulated in DepoFoam has potential as an alternative therapeutic treatment of hyperlipidemia...